المساهمون: Ali Aminian, Director of Bariatric and Metabolic Institute

المصدر: A Prospective Multicenter International Randomized Controlled Trial Comparing Surgical and Medical Therapies in the Treatment of Advanced Metabolic Dysfunction Associated Steatohepatitis

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06374875Test

المصدر: Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06256419Test

المؤلفون: Novo Nordisk Canada Inc.

المصدر: Impact of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Compared to Basal Insulin Start on Metabolic Targets in Patients Living With Type 2 Diabetes and Chronic Kidney Disease (Impact GLP-1 CKD)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06236672Test

المصدر: Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06182891Test

المؤلفون: American Society for Metabolic and Bariatric Surgery

المساهمون: Andrew Wheeler, Assistant Professor of Surgery

المصدر: Lee SJ, Sh SW. Mechanms, Pathophyslogy, and Management of Obesy. N Engl J Med. 2017 Apr 13;376(15):1491-2. do 10.1056/NEJMc1701944. No abstract avaable.
Mouton AJ, LX, Hall ME, Hall JE. Obesy, Hypertensn, and Cardc Dysfunctn: Novel Roles of munometabolm Macrophage Actatn and flammatn. Cc Res. 2020 Mar 13;126(6):789-806. do 10.1161/CCRESAHA.119.312321. Epub 2020 Mar 12.
Zhang Y, L J, Yao J, JG, Qn L, Wang J, Zhang G, Tn J, N Y, Zhang YE, Gold MS, L Y. Obesy: pathophyslogy and terventn. Nutrnts. 2014 Nov 18;6(11):5153-83. do 10.3390/nu6115153.
Schauer PR, Bhatt DL, Kwan JP, WolskK, Brethauer SA, Navaneethan SD, Amn A, Pothr CE, K ES, Nsen SE, Kashyap SR; STAMPEDE vestators. Bartr surgery versus tense medal therapy for dbetes--3-year outcomes. N Engl J Med. 2014 May 22;370(21):2002-13. do 10.1056/NEJMoa1401329. Epub 2014 Mar 31.
Blond E, Dse E, Cuerq C, DraJ, Valette PJ, Lavle M, Tholet C, Son C, Caussy C. EASL-EASD-EASO clal practe gueles for the management of non-alcohol fatty ler dease severely obese people: do they lead to over-referral? Dbetolog. 2017 Jul;60(7):1218-1222. do 10.1007/s00125-017-4264-9. Epub 2017 Mar 28.
de Wte D, Wngaarden LH, van Houten VAA, van den Dorpel MA, Brung TA, van der Harst E, Klaassen RA, Nzen RA. provement of Cardc Functn After Roux-en-Y Gastr Bypass Morbly Obese Patnts Whout Cardc Htory Measured by Cardc MR Obes Surg. 2020 Jul;30(7):2475-2481. do 10.1007/s11695-020-04543-y.
Schauer DP, Feelson HS, Koebnk C, Caan B, Wemann S, Leonard AC, Powers JD, Yenumula PR, Arterburn DE. Bartr Surgery and the Rk of Cancer a Large Multe Cohort. Ann Surg. 2019 Jan;269(1):95-101. do 10.1097/SLA.0000000000002525.
PuccA, Batterham RL. Mechanms underlyg the weht loss effects of RYGB and SG: sar, yet dferent. J Endocrol vest. 2019 Feb;42(2):117-128. do 10.1007/s40618-018-0892-2. Epub 2018 May 5.
Sakran N, Soer K, Hod K, Sherf-Dagan S, Soued S, Kessler Y, Adelson D, Bon R, Buchwald JN, Goe D, Razl A. Long-term Reported Outcomes Followg Prary Laparoscop Sleeve Gastrectomy. Obes Surg. 2023 Jan;33(1):117-128. do 10.1007/s11695-022-06365-6. Epub 2022 Nov 28.
Cooper TC, Smons EB, Webb K, Burns JL, Kushner RF. Trends Weht Rega Followg Roux-en-Y Gastr Bypass (RYGB) Bartr Surgery. Obes Surg. 2015 Aug;25(8):1474-81. do 10.1007/s11695-014-1560-z.
Abel SA, Englh WJ, Duke MC, Wlms DB, Aher CV, Broucek JR, Spann MD. Benefs of Adjuvant Medal Weht Loss terventn Settg of Weht Rega and adequate Weht Loss After Weht Loss Surgery. Am Surg. 2023 May;89(5):1857-1863. do 10.1177/00031348221078957. Epub 2022 Mar 22.
Blundell J, Flayson G, Axelsen M, Flt A, Gbons C, Kvt T, Hjerpsted JB. Effects of once-weekly semaglute on appete, energy take, control of eatg, food preference and body weht subjects wh obesy. Dbetes Obes Metab. 2017 Sep;19(9):1242-1251. do 10.1111/dom.12932. Epub 2017 May 5.
Astrup A, Carraro R, Fer N, Harper A, Kunesova M, Lean ME, Nkanen L, Rasmussen MF, Rsanen A, Rossner S, Savolaen MJ, Van Gaal L; NN8022-1807 vestators. Safety, toleraby and sustaed weht loss over 2 years wh the once-day human GLP-1 analog, laglute. t J Obes (Lond). 2012 Jun;36(6):843-54. do 10.1038/o.2011.158. Epub 2011 Aug 16. Erratum : t J Obes (Lond). 2012 Jun;36(6):890. t J Obes (Lond). 2013 Feb;37(2):322.
Hdso M, Hedback N, Svane MS, Moller A, Martussen C, Jorgensen NB, Dksen C, Gasbjerg LS, Krtnsen VB, Hartmann B, Rosenkde MM, Holst JJ, Madsbad S, Bojsen-Moller KN. The portance of Endogenously Secreted GLP-1 and G for Postprandl Glucose Tolerance and beta-Cell Functn After Roux-en-Y Gastr Bypass and Sleeve Gastrectomy Surgery. Dbetes. 2023 Mar 1;72(3):336-347. do 10.2337/db22-0568.
Garvey WT, Mechank J Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, PlodkowskR; Revwers of the AACE/ACE Obesy Clal Practe Gueles. AMERAN ASSOCTN OF CLAL ENDOCROLOGTS AND AMERAN COLLEGE OF ENDOCROLOGY COMPREHENSE CLAL PRACTE GUELES FOR MEDAL CARE OF PATNTS WH OBESY. Endocr Pract. 2016 Jul;22 Suppl 3:1-203. do 10.4158/EP161365.GL. Epub 2016 May 24.
Wunsawanya K, Chtoju S, Fantas KL, ModzelewskKL, Steenkamp D, Alexann SM. sul Requements Patnts Wh Type 2 Dbetes Undergog Bartr Surgery the patnt Settg and Upon Dcharge: A Sgle-Center Retrospecte Analys of sul Management Strategs. Endocr Pract. 2021 Jun;27(6):538-544. do 10.1016/j.eprac.2020.12.014. Epub 2021 Jan 11.
Sarma S, Palcu P. Weht loss between glucagon-le pepte-1 receptor agonts and bartr surgery adults wh obesy: A systemat revw and meta-analys. Obesy (Sver Sprg). 2022 Nov;30(11):2111-2121. do 10.1002/oby.23563.
Jensen AB, Renstrom F, Aczel S, Fol P, Baa-Steemann M, Beuschle F, Bz S. Effacy of the Glucagon-Le Pepte-1 Receptor Agonts Laglute and Semaglute for the Treatment of Weht Rega After Bartr surgery: a Retrospecte Observatnal Study. Obes Surg. 2023 Apr;33(4):1017-1025. do 10.1007/s11695-023-06484-8. Epub 2023 Feb 11.
Llewellyn DC, Logan Ell H, Aylw SJB, Ostaras E, Green S, Sheran W, Chew NWS, le Roux CW, Mas AD, Patel AG, Vcent RP, Drd GK. The effacy of GLP-1RAs for the management of postprandl hypoglycem followg bartr surgery: a systemat revw. Obesy (Sver Sprg). 2023 Jan;31(1):20-30. do 10.1002/oby.23600. Epub 2022 Dec 10.
Guaro D, MoronD, MarA, Rebelos E, CollnD, BaldS, Anselmo M, FerrannE, NannrM. Postprandl hypoglycaem after Roux-en-Y gastr bypass duals wh type 2 dbetes. Dbetolog. 2019 Jan;62(1):178-186. do 10.1007/s00125-018-4737-5. Epub 2018 Oct 12.
Madsbad S. Revw of head-to-head comparons of glucagon-le pepte-1 receptor agonts. Dbetes Obes Metab. 2016 Apr;18(4):317-32. do 10.1111/dom.12596. Epub 2015 Dec 29.
Hurtado A MD, Acosta A. Precn Mede and Obesy. Gastroenterol Cl North Am. 2021 Mar;50(1):127-139. do 10.1016/j.gtc.2020.10.005. Epub 2021 Jan 5.
de Vos WM, Tg H, Van Hul M, CanPD. Gut mrobme and health: mechant shts. Gut. 2022 May;71(5):1020-1032. do 10.1136/gutjnl-2021-326789. Epub 2022 Feb 1.
Shapo H, Kolodzjczyk AA, Halstuch D, Elav E. Be acs glucose metabolm health and dease. J Exp Med. 2018 Feb 5;215(2):383-396. do 10.1084/jem.20171965. Epub 2018 Jan 16.
Jonsson Bojsen-Moller KN, Krtnsen VB, Veedfald S, Wewer Albrechtsen NJ, Clausen TR, Kuhre RE, Rehfeld JF, Holst JJ, Madsbad S, Svane MS. Effects of Manulatg Cculatg Be Ac Concentratns on Postprandl GLP-1 Secretn and Glucose Metabolm After Roux-en-Y Gastr Bypass. Front Endocrol (Lausanne). 2021 May 14;12:681116. do 10.3389/fendo.2021.681116. eCollectn 2021.
Pournaras DJ, Glksman C, Vcent RP, Kuganolava S, Alaghband-Zadeh J, Mahon D, Bekker JH, GhateMA, Bloom SR, Walters JR, Welbourn R, le Roux CW. The role of be after Roux-en-Y gastr bypass promotg weht loss and provg glycaem control. Endocrology. 2012 Aug;153(8):3613-9. do 10.1210/en.2011-2145. Epub 2012 Jun 6.
ChaudharSN, Luo JN, Harr DA, Alkbarn H, Yao L, Pa D, Subramanm R, AdharAA, Vernon AH, K A, Wes ST, Huh JR, Sheu EG, Devl AS. A mrobl metabole remodels the gut-ler ax followg bartr surgery. Cell Host Mrobe. 2021 Mar 10;29(3):408-424.e7. do 10.1016/j.chom.2020.12.004. Epub 2021 Jan 11.
Jendle J, Hyotylaen T, Ores M, Nystrom T. Pharmacometabolom profes type 2 dbet subjects treated wh laglute or glepe. Cardvasc Dbetol. 2021 Dec 17;20(1):237. do 10.1186/s12933-021-01431-2.
Madsen MSA, Holm JB, Palleja A, Wmann P, Fabrs K, Rbolt K, Mkelsen M, Sommer M, Jelsg J, Nlsen HB, Vrang N, Hansen HH. Metabol and gut mrobme changes followg GLP-1 or dual GLP-1/GLP-2 receptor agont treatment dt-duced obese me. ScRep. 2019 Oct 30;9(1):15582. do 10.1038/s41598-019-52103-x.
Ocana-WhelmL, Mart-Nunez GM, Ru-Lon P, Alcae J, Garc-Fuentes E, Gutrrez-Repo C, Tahones FJ, Moreno-ds Gut Mrobta Metabolm of Be Acs Could Contrute to the Bartr Surgery provements Extreme Obesy. Metaboles. 2021 Oct 27;11(11):733. do 10.3390/metabo11110733.
Gente JKA, Olea KD, Perea JG, Tanaka DY, GuGN, Cadona MZ, SnReo DW, PerondMT. THE TESTAL MROBME PATNTS UNDERGOG BARTR SURGERY: A SYSTEMAT REVW. Arq Bras C D. 2022 Dec 19;35:e1707. do 10.1590/0102-672020220002e1707. eCollectn 2022.
Thakur U, BhansalA, Gupta R, RastogA. Laglute Augments Weht Loss After Laparoscop Sleeve Gastrectomy: a Randomed, Double-Bld, Placebo-Control Study. Obes Surg. 2021 Jan;31(1):84-92. do 10.1007/s11695-020-04850-4. Epub 2020 Jul 12.
Chaar ME, Lundberg P, Stoltzfus J. Thty-day outcomes of sleeve gastrectomy versus Roux-en-Y gastr bypass: fst report based on Metabol and Bartr Surgery Accredatn and Qualy provement Program database. Surg Obes Relat D. 2018 May;14(5):545-551. do 10.1016/j.soard.2018.01.011. Epub 2018 Jan 13.
Lew CA, de Jersey S, Seymour M, Hopks G, Hkman Osland E. on, Vam B12, Folate and Copper Defncy After Bartr Surgery and the pact on Anaem: a Systemat Revw. Obes Surg. 2020 Nov;30(11):4542-4591. do 10.1007/s11695-020-04872-y. Epub 2020 Aug 12.
James H, Lorentz P, Collazo-Clavell ML. Patnt-Reported Adherence to Emp Vam/Meral Supplementatn and Related Nutrnt Defncs After Roux-en-Y Gastr Bypass. Obes Surg. 2016 Nov;26(11):2661-2666. do 10.1007/s11695-016-2155-7.
Meyer Malsen S, Aaseth J, Flaten TP, Wht JE, Bjorke-Monsen AL. Essentl trace elements Norwegn obese patnts before and 12 months after Roux-en-Y gastr bypass surgery: Copper, manganese, selenm and zc. J Trace Elem Med Bl. 2020 Dec;62:126650. do 10.1016/j.jtemb.2020.126650. Epub 2020 Sep 21.
Ars PM, DomenonEA, Garc M, Esquel CM, Martez Lascano F, FoscarJM. Mronutrnt Defncs After Roux-en-Y Gastr Bypass: Long-Term Results. Obes Surg. 2020 Jan;30(1):169-173. do 10.1007/s11695-019-04167-x.
Biometabolic Impact of Continuation of GLP-1 Agonists Following Bariatric

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06132477Test

Other URLs: https://doi.org/10.15367/ch.v1i1.302Test

المساهمون: Francesco Giorgino, Professor

المصدر: Ahlqvt E, Storm P, KarajamakA, Martell M, Dorkhan M, Carlsson A, Vman P, Prasad RB, Aly DM, Almgren P, Wessman Y, Shaat N, Spegel P, Mulder H, Ldholm E, Melander O, Hansson O, Malmqvt U, Lernmark A, LahtK, Forsen T, TuomT, Rosengren AH, Groop L. Novel subgroups of adult-onset dbetes and the assoctn wh outcomes: a data-dren cluster analys of s varbles. Lancet Dbetes Endocrol. 2018 May;6(5):361-369. do 10.1016/S2213-8587(18)30051-2. Epub 2018 Mar 5.
Bello-Chavolla OY, Bahena-Lopez JP, Vargas-Vazquez A, Anton-Vla NE, Marquez-Salas A, Ferm-Martez CA, Rojas R, Mehta R, Cruz-Bautta Hernandez-Jenez S, Garc-Ulloa AC, Almeda-Valdes P, Aguar-Salas CA; Metabol Syndrome Study Group; Group of Study CAaD Clal characteratn of data-dren dbetes subgroups Mexans usg a reproducle mache learng approach. BMJ Open Dbetes Res Care. 2020 Jul;8(1):e001550. do 10.1136/bmjdrc-2020-001550.
Denn JM, Shlds BM, Henley WE, Jones AG, Hattersley AT. Dease progressn and treatment response data-dren subgroups of type 2 dbetes compared wh models based on sple clal features: an analys usg clal trl data. Lancet Dbetes Endocrol. 2019 Jun;7(6):442-451. do 10.1016/S2213-8587(19)30087-7. Epub 2019 Apr 29.
Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes: an Italian Monocentric Retrospective Study

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06120556Test

المساهمون: Xiao Li，MD, Associate professor of pharmacy

المصدر: Therapeutic Drug Use in Patients With Chronic Kidney Disease (CKD): a Multicenter Retrospective Real-world Study

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05818995Test

المصدر: The Exploreration of the Management for the Positive IAA in Patients With Type 2 Diabetes After Premix Insulin Therapy

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05578352Test

المصدر: FINErenone druG Utilization Study and Assessment of Temporal Changes Following Availability of Different Treatment Options in Patients With Chronic Kidney Disease and Type 2 Diabetes

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05526157Test

Other URLs: https://clinicaltrials.bayer.comTest/

المساهمون: Aureliane Pierret, Principle investigator

المصدر: Effect of Glucagon-like Peptide 1 (GLP1) Receptor Agonists on Mental Health in Patients With Obesity and Type 2 Diabetes (T2D): a Mixed Methods Study

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05492305Test